Abstract
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency characterized by marked reduction in all classes of serum immunoglobulins and the near absence of mature CD19(+) B-cells. Although malignancy has been observed in patients with XLA, we present the first reported case of acute myeloid leukemia (AML) in a patient with XLA. We also demonstrate the complete correction of the XLA phenotype following allogeneic hematopoietic cell transplantation for treatment of the patient's leukemia.
Keywords:
X-linked agammaglobulinemia; acute myeloid leukemia; stem cell transplantation.
© 2015 Wiley Periodicals, Inc.
MeSH terms
-
Agammaglobulinemia / complications
-
Agammaglobulinemia / therapy*
-
Allografts
-
Antibodies, Bacterial / biosynthesis
-
Antigens, CD19 / analysis
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
B-Lymphocyte Subsets / chemistry
-
Child, Preschool
-
Combined Modality Therapy
-
Genetic Diseases, X-Linked / complications
-
Genetic Diseases, X-Linked / therapy*
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use
-
Leukemia, Myeloid, Acute / complications
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myeloid, Acute / therapy*
-
Lymphocyte Count
-
Male
-
Peripheral Blood Stem Cell Transplantation*
-
Pneumococcal Vaccines
-
Recurrence
-
Remission Induction
-
Streptococcus pneumoniae / immunology
-
Transplantation Conditioning
Substances
-
Antibodies, Bacterial
-
Antigens, CD19
-
Immunoglobulins, Intravenous
-
Pneumococcal Vaccines
Supplementary concepts
-
Bruton type agammaglobulinemia